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Abstract: The treatment of dysphoric mania is challenging given the need to treat symptoms 
of both depression and mania simultaneously without provoking any clinical exacerbation. The 
newer antiepileptic drugs such as gabapentin, lamotrogine, and carbamazepine are often used 
as adjuncts to either lithium or valproic acid in the treatment of bipolar disorder. We decided to 
undertake a monotherapy trial because previous evidence suggested mixed states may be more 
responsive to anticonvulsants than more traditional antimanic agents. 51 patients with a DSM 
IV diagnosis of dysphoric mania were randomized to three groups comprising gapbapentin, 
lamotrogine or carbamazepine and followed for 8 weeks. Psychiatric diagnosis was veriﬁ  ed by 
the structural clinical interview for the DSM-IV (SCID). The MMPI-2 in full was used to assess 
symptoms at baseline and 8 weeks. All three groups showed signiﬁ  cant changes in MMPI-2 
scores for depression and mania subscales. Gabapentin showed the greatest change in depres-
sion symptom improvement relative to lamotrogine and carbamazepine, respectively. Although 
manic symptoms improved overall, here were no differences between groups in the degree of 
manic symptom improvement.
Keywords: dysphoric mania, manic-depression, depression, anticonvulsant, mood stabilizer
Introduction
The simultaneous presence of both manic and depressive symptoms referred to as mixed 
manic state or dysphoric mania has long been recognized (Kraepelin 1921; McElroy 
et al 1992; Swann et al 1993; Akiskal et al 1998; Cassidy et al 1998; Dilsaver et al 
1999). According to the DSM-IV, for the diagnosis of mixed manic state, two of four 
depressive symptoms in the setting of a manic syndrome appear to sufﬁ  ce and occurs 
in 50 percent of patients with bipolar disorder at some time (Akiskal 2005). Although 
dysphoric mania is a common disorder and the outcomes are generally poorer than 
pure manic and depressive episodes, little is known about how to treat such a condition 
and new evidence based strategies are needed.
Gabapentin, lamotrigine, and carbamazepine may be used either as monotherapies 
or as adjuncts to lithium and valproate, as there is some evidence that mixed states may 
be more responsive to anticonvulsants than more traditional anti-manic agents (Clothier 
et al 1992; McElroy et al 1992; Dilsaver et al 1993; Bowden 1995; Post et al 1996; 
Kruger et al 2005). The aim of this study is to determine the clinical effectiveness of 
gabapentin, lamotrogine, and carbamazepine in dysphoric mania.
The newer antiepileptic drugs such as lamotrigine and gabapentin show therapeutic 
beneﬁ  ts in bipolar disorder (Soutullo et al 1998; Berk 1999; Bowden et al 1999; Calabrese 
et al 1999; Sethi et al 2003) and generally have more favorable side effect proﬁ  les because 
of less weight gain, less drug interactions and less need for therapeutic monitoring Neuropsychiatric Disease and Treatment 2008:4(1) 228
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compared with older agents (Marken and Pies 2006). Whilst 
the anticonvulsants show growing evidence for the treatment 
of depressive symptoms in patients with bipolar disorder, as 
is seen in lamotragine (Bowden 1998; Bowden et al 1999, 
2003; Calabrese et al 1998, 1999; Macdonald and Young 2002; 
Yatham et al 2002; Ghaemi and Gaughan 2005; Muzina et al 
2005) and gabapentin (Ghaemi et al 1998; Altshuler et al 1999; 
Perugi et al 1999; Sokolski et al 1999; Young et al 1999; Vieta 
et al 2000; Macdonald and Young 2002; Wang et al 2002), it 
should be noted that more recent research does not support 
the use of these agents as antimanic agents (Pande et al 2000; 
Maidment 2001; Bowden 2002; Calabrese et al 2002).
An important treatment challenge in dysphoric mania is 
to bring about improvement in depressive symptoms without 
provoking the onset of manic symptoms. The studies referred 
to above however, were not designed to speciﬁ  cally treat 
mixed states but instead all manic episodes. In most studies, 
patients with mixed states accounted for a small subset of a 
total number of patients and thus extrapolation of these results 
to dysphoric mania patients as a whole should be considered 
with caution given the paucity of trials in the literature regard-
ing the treatment of depressive features in mania (Vieta et al 
2000). Despite limited evidence, concomitant anticonvulsants 
are used frequently in mixed manic patients. Therefore, we 
designed this clinical trial to compare the efﬁ  cacy of mono-
therapy with lamotrigine, carbamazepine, or gabapentin in 
patients with dysphoric mania.
The MMPI-2 was selected to measure clinical symptoms 
of mania and depression. The MMPI-2 has been validated in 
Iran and multiple groups have received training at numerous 
academic centers resulting in excellent inter-rater reliability 
(Duckworth and Anderson 1995; Mootabi Pers Comm 1995). 
Unfortunately the YMRS was not validated at the time of this 
study and the HAM-D (Hamilton Rating Scale for Depres-
sion) was not used as a single measure incorporating both 
mania and depression scores was required. Furthermore, the 
MMPI-2 is known for cross-cultural sensitivity. This has 
provided an instrument with religious and cultural contexts, 
which may be more appropriate for an Iranian study (Butcher 
2004). For this reason the MMPI-2 in combination with the 
SCID were chosen as structured instruments.
Materials and methods
Subjects
A total of 59 patients entered the double blind, ﬁ  xed dose, 
randomized study. Eight subjects were discontinued from the 
study due to adverse events. A total of 51 subjects completed 
the study, including 28 women and 23 men. The subjects 
ranged in age from 18–60 years (Table 1). All patients were 
recruited from two academic psychiatric outpatient clinics, 
Ghaem and Avecina hospitals, in Mashad, Iran. All patients 
met DSM-IV criteria for dysphoric mania. Patients had a 
history of bipolar I disorder with at least one prior manic 
episode, and a recent mild to modest but not severe mixed 
manic attack. No patients had current psychotic features.
Subjects with any other DSM-IV diagnosis requiring psy-
chopharmacological treatment were excluded from the study. 
Alcohol and substance dependence or use within 1 month 
prior to study start date, and use of psychotropic medication 
for 3 months prior to study start date were also excluded from 
the study. Women of childbearing potential who were without 
adequate contraception were also excluded from the study. 
Subjects did not differ signiﬁ  cantly with regard to demo-
graphic variables including age, sex, or educational level.
All subjects required a minimum reading level of grade 8 
comprehension to be included in the study and have enough 
compliance to answer the questions necessary to participate 
in the MMPI-2. Therefore patients in a stage of disorganized 
mania were excluded from the study. All subjects underwent a 
medical and neurological examination and a series of labora-
tory tests for safety. Informed written consent was obtained 
from all subjects. The protocol was approved by the ethics 
committee of Mashhad University of Medical Sciences, 
Mashad, Iran. The trial was performed in accordance with 
the declaration of Helsinki.
Drug therapy
Subjects were randomized to three groups, group 1 (gabapen-
tin, 900 mg/day, N = 18), group 2 (lamotrigine, 100 mg/day, 
N = 20), and group 3 (carbamazepine, 600 mg/day N = 13). 
Table 1 Patient baseline characteristics in an 8-week, randomized, 
single-blind trial of carbamazepine, lamotrigine, and gabapentin for 
treatment of dysphoric mania
Gabapentin   Lamotrigine  Carbamazepine  Characteristic
(N = 18)  (N = 20)   (N = 13)
28.94 ± 10.63  27.80 ± 7.65  28.92 ± 9.58  Age (years)
    (Mean  ± SD)
9/9 11/9  8/5  Female/male 
48.33 ± 8.48  37.80 ± 9.03  42.08 ± 8.63  Depression
    scores*
    (Mean  + SD) 
26.11 ± 3.14  25.25 ± 3.78  24.85 ± 2.07  Mania score**
    (Mean  + SD)
Abbreviations: MMPI-2, Minnesota Multiphasic Personality Inventory-2; N, number 
of patients who completed the study; SD, standard deviation.
Notes: *Depression scores of depression subscale in MMPI-2 test; **Mania score of 
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Carbamazepin was in regular formation form. All three 
medications were initiated at low doses, Patients received 
carbamazepine 400 mg/day (twice-daily dosing), lamotrigine 
25 mg/day at night and gabapentin 300 mg/day divided in three 
doses. The doses of carbamazepine, lamotrigine and gabapen-
tin were increased to a target dose of 600, 100 and 900 mg/day, 
respectively within 2 weeks at which remained ﬁ  xed until the 
end of study. Clinical assessments were carried out at the ﬁ  rst 
visit (week 0), followed weekly until visit 3 (week 2) and then 
at 2-week intervals to visit 6 (8 weeks).
Clinical assessment
A detailed psychiatric interview by a psychiatrist was 
obtained at baseline and at the ﬁ  nal visit. In addition, a 
structured clinical interview (SCID) was performed by a 
psychiatrist, with the patient and their family at the baseline 
visit. A single psychiatrist performed all ratings to reduce 
inter-rater error. In addition, patients with the assistance of 
their families ﬁ  lled out a questionnaire regarding gender, 
past medical and drug history, and other demographic 
information. Depression and mania symptoms were evaluated 
using subscales of the Minnesota multiphasic personality 
inventory 2 (MMPI-2). A single psychologist at baseline and 
at the ﬁ  nal visit administered the 104-question test.
Blinding
Both the psychiatrist completing the interviews and the 
psychologist administering the MMPI-2 were blind to the 
treatment groups throughout the study period. Serum drug 
levels were not obtained in the study.
Statistical analysis
Only patients who had completed the study were included in 
demographic and efﬁ  cacy analyses. Response to treatment 
regarding changes in depressive and manic scores was 
determined using analysis of variance (ANOVA). A t-test was 
used for comparisons of depression and mania scores between 
groups. For all analyses, p   0.05 was deﬁ  ned as statistically 
signiﬁ  cant. All statistical analyses were performed using 
SPSS version 11.
Results
The primary outcome measure was baseline versus endpoint 
change in the MMPI-2 scores.
Total changes in depression and mania 
scores following 8 weeks treatment
A significant change in mean total score on both the 
depression and mania subscales of MMPI-2 was observed 
following treatment for each of the three groups (Figures 1 
and 2). The percent changes in depression scores for each of 
the three groups were as follows: gabapentin, 50% decrease 
(p   0.000), lamotrigine 33% decrease (p   0.000), and 
carbamazepine 13% decrease (p   0.005). For carbamazepine, 
lamotrigine and gabapentin respectively, the percent change 
in mania score for each of the three groups were as follows: 
gabapentin 75% decrease (p   0.000), lamotrigine 64% 
decrease (p   0.000), and carbamazepine 59% decrease 
(p   0.000) (Tables 2 and 3).
Between group differences: depression 
and mania symptoms
There was a signiﬁ  cant (p   0.05) effect on total mania 
score improvement in all three groups. The mean change of 
total mania scores on hypomania subscale in MMPI-2 test 
was greater in gabapentin than carbamazepine (p = 0.046). 
The results were also analyzed in subdimensions of mania 
Figure 1. Mean change of depression subscale of MMPI-2 test from the baseline to the endpoint in an 8-week, Randomized, Single-Blind Trial of Carbamazepine, Lamotrigine 
and Gabapentin for treatment of Dysphoric mania.
Abbreviations: MMPI-2, Minnesota Multiphasic Personality Inventory-2; CBZ, carbamazepine; LTG, lamotrigine; GBP, gabapentin.
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in MMPI-2 test, that showed a greater improvement in 
psychomotor acceleration (M2) in gabapentin than carbam-
azepine (p = 0.003). The improvement in other subdimensions 
of mania did not show statistically signiﬁ  cant difference 
among groups (Table 4).
Signiﬁ  cantly greater improvement in the mean total score 
on depression subscale of MMPI-2 test was observed in the 
gabapentin group when compared to lamotrigine (p = 0.000) 
and in gabapentin and lamotrigine as compared to carbam-
azepine (p = 0.000, p = 0.040, respectively) (Table 4).
Depressive symptom subscale 
assessment: gabapentin vs lamotrigine vs 
carbamazepine
An additional analysis on the depression symptoms of each 
patient was completed to compare the three treatments (Figure 3). 
There are 5 subdimensions of the depression subscale. These 
subdimensions rate the following depressive symptoms: 
D1 subjective depression, D2 psychomotor retardation, D3 
body dysfunction, D4 mental dullness, D5 brooding.
Treatment effects in 5 subdimensions of depression 
subscale in MMPI 2 test showed that improvement in the 
mean scores of psychomotor retardation and body dysfunction 
(D2 and D3) were signiﬁ  cantly greater in gabapentin and 
lamotrigine than in carbamazepine (p = 0.023 and p = 0.0031 
in D2, and p = 0.000 and p = 0.000 in D3, respectively). In the 
carbamazepine group, the mean scores on these subdimensions 
of depression increased by 0.85 in psychomotor retardation 
and 1.15 in body dysfunction, indicating the condition was 
worsened. Improvements in the mean scores of mental dullness 
and brooding (D4 and D5) were signiﬁ  cantly greater (p   0.01) 
in gabapentin than lamotrigine and carbamazepine.
Depression subscale: improvement in 
subjective depression scores
As it is important to evaluate that the improvement in 
depression score is related to the change in depressive 
associated symptoms or to the depressive mood itself, 
we analyzed the efﬁ  cacy of drugs in reducing depressed 
mood (MMPI-2 subscale D1: subjective depression) scores 
and compared it with other subdimensions of depression 
subscale in MMPI-2. Mean percentage improvement in 
the depression subdimensions of depression subscale in 
MMPI-2 test showed greater improvement in depressed 
mood (D1-subjective depression) than other subdimenions 
of depression (Figure 3).
Figure 2. Mean change of mania subdimensions of hypomania subscale of MMPI-2 test from the baseline to the endpoint in an 8-week, Randomized, Single-Blind Trial of 
Carbamazepine, Lamotrigine and Gabapentin for treatment of Dysphoric mania.
Abbreviations: MMPI-2,Minnesota Multiphasic Personality Inventory-2; CBZ, carbamazepine; LTG, lamotrigine; GBP, gabapentin.
Table 2 Mean percentage change of depression and hypomania subscales of MMPI-2 test from the baseline to the endpoint in an 
8-week, randomized, single-blind trial of carbamazepine, lamotrigine, and gabapentin for treatment of dysphoric mania
Change % (Mean percentage)  After therapy  Before therapy
Hypomania scores  Depression scores  Hypomania scores  Depression scores  Hypomania scores  Depression scores
   (Mean  ± SD)  (Mean ± SD)  (Mean ± SD)  (Mean ± SD)
74.98 ± 13.06  50.02 ± 11.48  6.50 ± 3.60  23.83 ± 5.66  26.11 ± 3.14  48.33 ± 8.48
64.69 ± 12.19  33.45 ± 15.44  8.75 ± 2.65  23.30 ± 4.74  25.25 ± 3.78  37.70 ± 9.03
58.80 ± 25.70  13.56 ± 15.64  9.85 ± 5.56  35.54 ± 5.50  24.77 ± 2.00  42.08 ± 8.62
Abbreviations: MMPI-2, Minnesota Multiphasic Personality Inventory-2; SD, standard deviation.
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Baseline differences
There were no demographic differences found between groups 
in age, gender or educational level. There were no differences 
in baseline mania scores between groups however there were 
differences in baseline depression scores between groups 
(Table 5). The total depression subscale of the MMPI-2 was 
signiﬁ  cantly higher in the gabapentin than lamotrigine group 
(48.33 vs 37.80 p = 0.002). This effect was also seen across all 
subdimension scores on the depression subscale of the MMPI-2. 
Carbamazepine depression scores at baseline were also higher 
than lamotrigine scores, though not signiﬁ  cantly higher.
Rescue medication
Lorazepam up to 4 mg/day was permitted for the manage-
ment of agitation or insomnia only during the ﬁ  rst two weeks 
of the study. No other adjunctive psychotropic medications 
were permitted during the study.
Safety
Safety ratings were carried out at the ﬁ  rst visit, followed 
weekly until visit three and then at 2 week intervals to visit 
6 (8 weeks). Safety ratings included assessment of vital 
signs and adverse events detected by clinical evaluation and 
spontaneous reports of patients and their families at each 
visit. Laboratory tests were conducted at baseline of the 
study and included: blood count, fasting blood sugar, liver 
function tests, electrolytes, blood urea nitrogen, serum creati-
nine, thyroid function test, and urine analysis. Eight subjects 
were withdrawn from the study due to adverse events. Six 
subjects (31%) withdrew from the carbamazepine group due 
to gastrointestinal upset and/or vertigo and 2 subjects (11%) 
withdrew from the gabapentin group due to severe drowsiness 
and/or skin itching.
Discussion
Anticonvulsant therapy using gabapentin, lamotragine, 
or carbamazepine is effective in the treatment of mild to 
moderate dysphoric mania. All treatments showed sig-
niﬁ  cant improvement in depression and mania symptoms 
relative to baseline. Gabapentin showed the greatest 
change in depression symptom improvement relative to 
lamotrigine and carbamazepine, respectively. There were no 
signiﬁ  cant differences between groups in manic symptom 
improvement.
To our knowledge, this is the ﬁ  rst study to systematically 
evaluate monotherapy with carbamazepine, lamotrigine, and 
gabapentin in patients with dysphoric mania. Indeed this is 
one of the ﬁ  rst randomized ﬁ  xed dose trials observing the 
three anticonvulsants in an 8 week trial using validated clinical 
instruments in Iran. The study concluded that monotherapy 
with gabapentin, lamotrigine and carbamazepine was 
effective treating mixed states as shown by significant 
changes to the MMPI following treatment and the effects 
of gabapentin were superior to lamotrigine and lamotrigine 
was superior to carbamazepine. However in the absence or a 
parallel placebo control group we cannot conclude that this 
effectiveness is equivalent to efﬁ  cacy.
In our study gabapentin provided signiﬁ  cantly greater 
symptom improvement in depression scores than lamotrigine. 
This ﬁ  nding is in accordance with Sokolski and colleagues 
(1999) who showed a rapid action of gabapentin against the 
depressive symptoms of the mixed state. Numerous studies 
have reported the beneﬁ  ts of lamotrigine on depressive symp-
toms (Bowden 1998; Bowden et al 1999, 2003; Calabrese 
Table 3 Between group differences in mean percentage change 
of depression and hypomania subscales of MMPI-2 test scores 
analyzed with ANOVA test
Measure Mean  square  F Sig
Depression* 5025.88  24.85  0.00*
mania** 1062.73  7.38  0.03*
Abbreviations: ANOVA, Analysis of Variance; F, F ratio; MMPI-2, Minnesota Multi-
phasic Personality Inventory-2; Sig, signiﬁ  cance.
Notes: *Depression scores of depression subscale in MMPI-2 test; **Mania score 
of hypomania subscale in MMPI-2 test.
Table 4 Between group differences in mean change of 
depression and hypomania subscale of MMPI-2 test scores 
analyzed with ANOVA test
Measure Mean  square  F  Sig
D1 – Subjective   87.43  2.27  0.11 
Depression score       
D2 – Psychomotor   57.93  4.50  0.02* 
Retardation score     
D3 – Body Dysfunction  81.40  16.13  0.00* 
score    
D4 – Mental Dullness   88.37  6.77  0.003* 
score    
D5 – Brooding score  42.79  7.26  0.002* 
Total Depression   1290.71  21.34  0.00* 
subscale score     
M1 – Amorality score  0.243  0.08  0.92
M2 – Psychomotor   42.65  6.25  0.004*
Acceleration score     
M3 – Imperturbability  0.164  0.05  0.95
score    
M4 – Ego Inﬂ  ation   11.11  2.22  0.12
score    
Hypomania subscale  90.92  3.31  0.04*
score    
Abbreviations: ANOVA, Analysis of Variance; F, F ratio; MMPI-2, Minnesota Multipha-
sic Personality Inventory-2; Sig, signiﬁ  cance.Neuropsychiatric Disease and Treatment 2008:4(1) 232
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et al 1998, 1999; Macdonald and Young 2002; Yatham et al 
2002; Ghaemi and Gaughan 2005; Muzina et al 2005), and 
indeed lamotrigine was effective in the treatment of depres-
sive symptoms in our study. The reason why gabapentin may 
have superceded lamotrigine in our study might be related to 
a lower baseline depression score in lamotrigine group, thus 
leaving little room for symptom improvement.
Gabapentin was superior to carbamazepine for reducing 
depression and mania symptoms. Although some trials 
fail to show clear antimanic efﬁ  cacy of gabapentin (Carta 
et al 2003), Erfruth and colleagues (1998) and Grunze and 
colleagues (1999) suggest that monotherapy with gabapentin 
might be useful in selected patients to treat modest but not 
severe manic states. Our study suggests that gabapentin may 
be helpful for the treatment of depression in some bipolar 
patients.
Of particular concern in our study were earlier reports 
have suggested an association between lamotrigine and 
gabapentin use and subsequent manic or hypomanic episodes 
(Short and Cooke 1995; Leweke et al 1999; Margolese 
et al 2003). However, most of these reports were isolated 
events inﬂ  uenced by a variety of confounding factors. In our 
study, lamotrigine and gabapentin were well tolerated and 
there was no evidence of exacerbation of manic symptoms. 
Moreover, all of these agents were more effective on manic 
symptoms than depressive symptoms (Figures 1 and 2) as 
shown by the mean percentage decrease in total depression 
and mania scores.
In our study, carbamazepine, lamotrigine, and gabapentin 
had a clear effect on depressed mood (D1 – subjective depres-
sion). Therefore the improvement in depression score was 
due to a real improvement in depressive mood, not merely 
in depressive associated symptoms. This ﬁ  nding is support 
by Baker and colleagues (2003) on a reanalysis of the two 
studies performed by Tohen and colleagues (1999, 2000) who 
showed that the use of olanzapine in reducing total HAM-D 
scores was more directed to reducing somatic and paranoid 
symptoms than to depressive mood itself.
Our study has several limitations and include: lack of a 
control group, no comparison to valproate or lithium, use of 
the MMPI as a clinical instrument instead of the YMRS or the 
HAM-D, randomization imbalances due to dropouts, variance 
in severity of depression scores at baseline between groups, 
Table 5 Between group differences in baseline depression and 
hypomania subscales of MMPI-2 test scores analyzed with ANOVA 
test
Measure Mean  square  F  Sig
D1 – Subjective   52.65  1.16  0.323
Depression score     
D2 – Psychomotor   7.83  0.85  0.433
Retardation score     
D3 – Body dysfunction  27.39  6.58  0.003*
score    
D4 – Mental dullness   31.86  4.86  0.02*
score    
D5 – Brooding score  19.43  4.86  0.012*
Total Depression   528.02  6.92  0.002*
subscale score     
M1 – Amorality score  0.87  0.67  0.518
M2 – Psychomotor   21.34  5.77  0.006*
Acceleration score     
M3 – Imperturbability  2.10  1.53  0.294
score    
M4 – Ego Inﬂ  ation   0.34  0.14  0.869
score    
Hypomania subscale  7.34  0.72  0.491
score    
Abbreviations: ANOVA, Analysis of Variance; F, F ratio; MMPI-2, Minnesota Multi-
phasic Personality Inventory-2; Sig, signiﬁ  cance.
Figure 3. Mean Percentage Improvement in the depression subdimensions of depression subscale in MMPI-2 test in an 8-week, Randomized, Single-Blind Trial of Carbamazepine, 
Lamotrigine and Gabapentin for treatment of Dysphoric mania.
Abbreviations: MMPI-2, Minnesota Multiphasic Personality Inventory-2; CBZ, carbamazepine; LTG, lamotrigine; GBP, gabapentin; D1, Subjective Depression; D2, Psychomotor 
Retardation; D3, Body dysfunction; D4, Mental Dullness; D5, Brooding.
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relatively small sample size, low ﬁ  xed dose of medication, 
and no serum drug levels were obtained.
In regard to the dose, we used a relatively low ﬁ  xed 
dose of medication, in view of the subject selection crite-
ria, which excluded patients in severe manic episode (that 
commonly are treated by adjunct therapy). However, all 
medications were within the therapeutic window of treat-
ment for dosage. In addition, subjects were obtained from 
academic psychiatric outpatient clinics and may not be 
representative of community patients. Finally, we could not 
monitor the blood levels of the drugs due to local hospital 
limitations. Yet, despite all of these limitations we observed 
highly signiﬁ  cant improvement from baseline following 
treatment in all three medication groups after 8 weeks, 
these results may therefore indicate effectiveness of these 
anticonvulsants in the monotherapy treatment of mild to 
moderate dysphoric mania.
In comparison with other studies in the ﬁ  eld, our study 
had both strengths and weaknesses. For example, our study 
did not allow patients to titrate to maximal efﬁ  cacy nor were 
serum blood levels obtained to compare with therapeutic 
efﬁ  cacy. Unlike most other studies on the anticonvulsants 
we did not make comparisons to either lithium or valproic 
acid. Our study did have excellent inter-rater reliability and 
advanced training on the clinical instruments, a factor often 
missing in other studies. In addition there were no serious 
adverse events reported in the study. Finally the use of the 
YMRS (Young mania rating scale) as a measurement for end 
point analysis could have been a better choice had this option 
been available in Iran, as this instrument has been more com-
monly used to assess manic symptoms in the literature.
Implications for further research
Dysphoric mania is common, severe, and resistant to treat-
ment, therefore further studies are warranted with larger 
sample sizes. Future studies should examine the effects of 
these anticonvulsants in monotherapy and in adjunct therapy 
with lithium and valproate. Further research is also needed to 
fully clarify the role of new agents with putative antidepressant 
properties. In addition psychiatric structured clinical inter-
views like the SCID when combined with psychological test 
batteries such as the MMPI provide validity for studies using 
clinical endpoint analysis in areas of cultural diversity.
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